Roche Holding stock ends the day higher in after-hours trading

Roche Holding stock, represented by its U.S.-listed ADRs, closed higher on the OTCQX market on September 21, 2026, ending the regular session up in percent terms compared with the prior close based on OTC data in U.S. dollars. The move left the ADRs ahead of a broadly steady U.S. benchmark index, underscoring relative strength in the name. A positive European approval for the company’s eye drug Susvimo added a further support factor for sentiment.

September 21, 2026 in numbers

Roche Holding AG (ISIN CH0012032048, OTCQX: RHHBY) saw its ADRs advance during the U.S. regular session on September 21, 2026, with the closing price on the OTCQX market in U.S. dollars marking a gain of more than 2 percent versus the prior close, according to OTC trading data. During the day the ADRs traded within a defined intraday range between their opening level and session high and low, with the close sitting comfortably within that band. In Switzerland the underlying Roche shares on SIX Swiss Exchange finished the home session higher as well, with local data showing a gain of around 2 percent by the official close in Basel at 11:35 a.m. ET, the difference in percentage terms reflecting the exchange rate between Swiss francs and U.S. dollars.

As Seeking Alpha reported on September 21, 2026, Roche obtained European approval for its eye implant Susvimo to treat neovascular age-related macular degeneration, which was cited alongside a roughly 2.4 percent advance in the ADRs. Additional European market commentary from Newsquawk highlighted the European Commission approval of Susvimo for the same indication, reinforcing this regulatory milestone as a key driver of the day’s strength. Per European trading data cited by finanzen portals, Roche’s Swiss-listed shares were also up around 2 percent by the afternoon home-market close, in line with the ADR performance.

After the bell and next trading day

After the closing bell on September 21, 2026, Roche’s ADRs continued to be quoted on the OTCQX marketplace, with after-hours indications broadly consistent with the regular-session gains and no marked reversal according to late-afternoon OTC quote overviews. Sector context remained supportive, with other large pharmaceutical names showing modest gains and selected biotech peers under pressure, as noted by a cross-stock comparison on TradingView where Roche’s ADRs were indicated up about 2.4 percent against a weaker biotech name. Looking ahead to the next U.S. trading day on September 22, 2026, investors will continue to focus on the implications of the Susvimo approval for Roche’s ophthalmology franchise and any further regulatory or pipeline updates from the company, as well as broader moves in the S&P 500 and health care sector indices that could influence the ADRs’ relative performance.